|
|
Article: Oncolytics Biotech Inc. Announces Conclusion of Patient Follow Up in Canadian Phase I Recurrent Malignant Glioma Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- January 17, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CALGARY, Jan. 17 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the six-month follow up period has been concluded for patients in its Phase I Canadian recurrent malignant glioma clinical trial. As reported in October 2005, intratumoural administration of reovirus was well tolerated by the patients and a maximum tolerated dose was not reached. Surviving patients continue to be monitored and data analysis is ongoing.
"We intend to continue to investigate REOLYSIN(R) as a monotherapy in our U.S. Phase I/II malignant glioma clinical trial, employing an alternative delivery method," said Dr. Brad Thompson, ...